Anixa Biosciences (ANIX) director purchases 12,000 shares of common stock
Rhea-AI Filing Summary
Lewis H. Titterton Jr., a director of Anixa Biosciences Inc, purchased 12,000 shares of common stock on July 20, 2026 at $3.47 per share in a transaction classified as a purchase in open market or private transaction, bringing his direct holdings to 986,967 shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 12,000 shares
Net Buy
1 txn
Insider
Titterton Lewis H jr
Role
Director
Bought
12,000 shs ($42K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 12,000 | $3.47 | $42K |
Holdings After Transaction:
Common Stock — 986,967 shares (Direct)
Key Figures
Shares purchased: 12,000 shares
Purchase price per share: $3.47
Shares owned after transaction: 986,967 shares
3 metrics
Shares purchased
12,000 shares
Common stock purchase by Lewis H. Titterton Jr. on July 20, 2026
Purchase price per share
$3.47
Per-share price for the 12,000 common shares acquired
Shares owned after transaction
986,967 shares
Direct common stock holdings of Lewis H. Titterton Jr. following the purchase
Key Terms
Common Stock, non-derivative, Purchase in open market or private transaction
3 terms
Common Stock financial
"security_title: Common Stock for the reported transaction"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
non-derivative financial
"transaction_type: non-derivative for the common stock purchase"
Purchase in open market or private transaction financial
"transaction_code_description: Purchase in open market or private transaction"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did ANIX report for Lewis H. Titterton Jr.?
Anixa Biosciences reported that director Lewis H. Titterton Jr. purchased 12,000 shares of common stock. The transaction occurred on July 20, 2026 and was classified as a purchase in an open-market or private transaction at a stated per-share price.
Was the ANIX insider transaction a buy or sell, and on what date?
The transaction was a buy, specifically a purchase of common stock by director Lewis H. Titterton Jr. It took place on July 20, 2026, and is coded as a purchase in an open market or private transaction in the Form 4 details.
Does this ANIX Form 4 involve derivative securities?
No, this Form 4 transaction involves non-derivative securities, specifically Anixa Biosciences common stock. The filing classifies the security type as non-derivative, and the derivative summary section reports no derivative transactions or remaining derivative positions in this particular report.